A spike in M&A activity and stock prices have pulled biotech out of a yearslong downturn. But regulatory tumult and fierce ...

On a conference call, executives cited “confusion” and declining vaccination rates in the U.S. while discussing a quarterly ...

AstraZeneca’s investment will “span the value chain” of drug research and development and comes amid a prolonged surge in ...

The biotech also raised $235 million in debt and equity funding to support marketing of the drop, which it claims to be an ...

The potentially $1 billion alliance centered around a flexible gene editing technology adds to a portfolio of cutting-edge ...

Still, the medications in the latest round of negotiations — which now includes “Part B” drugs given in doctors offices — ...

Halozyme is paying as much as $400 million for a drug delivery specialist that could boost its growth prospects, one analyst ...

The development of a brain tumor in a study participant led regulators to suspend a Hurler syndrome therapy in early testing ...

TRex Bio banked a Series B extension to advance its atopic dermatitis program, which is competing in a crowded field.

Intellia is instituting new safeguards following the death of a study participant that led regulators to pause two trials in ...

A drug Roche acquired in a multibillion-dollar deal could be as effective as Zepbound, but may struggle to stand out in a ...

The ongoing surge in licensing deals for early drug prospects should continue this year and involve more cell and gene ...